trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Two prophylactic vaccines have been developed against high risk HPV types 16 and 18 for the prevention of cervical cancer.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
3 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that two prophylactic vaccines have been developed against high risk HPV types 16 and 18 for the prevention of cervical cancer?

Yes. Multiple studies and reviews confirm that prophylactic vaccines targeting high-risk HPV types 16 and 18 have been successfully developed and implemented to prevent cervical cancer and its precursors.

Verdict: SUPPORTED · 3 sources for, 0 against · Last checked

The analysis

The retrieved papers consistently confirm that prophylactic HPV vaccines targeting high-risk types 16 and 18 have been developed and are utilized globally for cervical cancer prevention, supported by strong umbrella review and clinical evidence.

Evidence for · 3
New Approaches to Prophylactic Human Papillomavirus Vaccines for Cervical Cancer Prevention
2011
Paper notes that currently licensed human papillomavirus vaccines protect against select high-risk types to prevent cervical cancer precursors.
Get citation
Gersch, E. D., Gissmann, L., & Garcea, R. L. (2011). New Approaches to Prophylactic Human Papillomavirus Vaccines for Cervical Cancer Prevention. doi.org. https://doi.org/10.3851/imp1941

See more details
More for · 2
The population impact of human papillomavirus vaccination on cancer and pre-cancer outcomes: An umbrella review of meta-analyses.
2026
Umbrella review highlights high efficacy of prophylactic HPV vaccines against HPV16/18 infection and precancerous lesions.
Get citation
F, R. & Ü, A. (2026). The population impact of human papillomavirus vaccination on cancer and pre-cancer outcomes: An umbrella review of meta-analyses.. doi.org. https://doi.org/10.1080/21645515.2026.2699584

Mismatch Between Vaccine Targets and Endemic HPV Genotypes in Sarawak, East Malaysia: Implications for Cervical Cancer Prevention.
2026
Study explicitly discusses bivalent and quadrivalent prophylactic HPV vaccines targeting high-risk types 16 and 18 for cervical cancer prevention.
Get citation
AR, J., V, N., AA, S., ACS, B., J, A., NT, S., A, I., YY, K., D, S., SF, I., & CS, T. (2026). Mismatch Between Vaccine Targets and Endemic HPV Genotypes in Sarawak, East Malaysia: Implications for Cervical Cancer Prevention.. doi.org. https://doi.org/10.1002/jmv.71010

What does the evidence say?

The retrieved papers consistently confirm that prophylactic HPV vaccines targeting high-risk types 16 and 18 have been developed and are utilized globally for cervical cancer prevention, supported by strong umbrella review and clinical evidence.

Receipt History
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work